VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9861
+0.0161 (+1.66%)
At close: 4:00PM EDT

1.0100 +0.02 (2.42%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close0.9700
Open0.9700
Bid0.9900 x 1000
Ask1.0100 x 900
Day's Range0.9700 - 1.0373
52 Week Range0.8500 - 6.7900
Volume161,572
Avg. Volume835,618
Market Cap24.511M
Beta14.36
PE Ratio (TTM)N/A
EPS (TTM)-5.0950
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • GlobeNewswire28 days ago

    Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced V-Go has launched and is now available in Australia through its previously disclosed exclusive distribution agreement with AMSL Diabetes. “We are pleased to announce V-Go Wearable Insulin Delivery device is now available for patients with type 2 diabetes in Australia,” said Valeritas CEO, John Timberlake.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of VLRX earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Valeritas Holdings Inc Earnings Call

  • GlobeNewswirelast month

    Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth

    BRIDGEWATER, N.J., Aug. 07, 2018-- Valeritas Holdings, Inc., a medical technology company and maker of V-Go ® Wearable Insulin Delivery device, a simple, affordable, all-in-one, insulin delivery option ...

  • ACCESSWIRElast month

    Valeritas Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Valeritas Holdings, Inc. (NASDAQ: VLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • GlobeNewswirelast month

    Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that its distribution partner in Austria and Germany, MED TRUST, has exercised the rights to promote, market, and sell V-Go to diabetes clinics and patients in the Czech Republic and Slovakia. “We are excited that our partner, MED TRUST, has decided to expand its original distribution agreement to also include the Czech Republic and Slovakia,” said Valeritas CEO John Timberlake.

  • GlobeNewswire2 months ago

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today a poster titled “Use of V-Go® Wearable Insulin Delivery device by Advanced Practitioners Demonstrated Improved Clinical Benefits in Patients with Type 2 Diabetes Uncontrolled on Multiple Daily Injections of Insulin” will be unveiled today at the Metabolic & Endocrine Disease Summit (MEDS) conference in San Diego, California. The analysis showed that insulin-dependent patients with uncontrolled type 2 diabetes clinically benefited after switching to V-Go from multiple daily injections (MDI). “For many patients with type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” said Amanda Patricia Wakim, DNP, FNP-BC an endocrinology-focused nurse practitioner in Wheeling, West Virginia.

  • GlobeNewswire2 months ago

    Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced V-Go is now available in New Zealand through its exclusive distribution agreement with NZMS Diabetes. “We are delighted to announce patients with type 2 diabetes in New Zealand now have access to V-Go® Wearable Insulin Delivery device,” said Valeritas CEO, John Timberlake.

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX).

  • GlobeNewswire2 months ago

    Valeritas, Makers of V-Go® Insulin Delivery, is a Contributing Supporter of the Interactive Insulin Workshop at Two MEDS Conferences

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device for patients with diabetes, today announced their support of the interactive insulin workshops at the upcoming Metabolic & Endocrine Disease Summit (MEDS) programs. The first conference runs August 1-4, 2018, in San Diego, CA, with the Insulin Workshop on Saturday, August 4.  It is followed by an Orlando, FL, summit from October 10-13, 2018.

  • GlobeNewswire2 months ago

    Valeritas to Report Second Quarter 2018 Results August 7, 2018

    BRIDGEWATER, N.J., July 24, 2018-- Valeritas Holdings, Inc., a medical technology company and maker of V-Go ® Wearable Insulin Delivery device--- a simple, all-in-one, wearable insulin delivery option ...

  • Benzinga3 months ago

    Valeritas Stock Should More Than Double, Oppenheimer Says

    Valeritas Holdings Inc (NASDAQ: VLRX ), a medical technology company known for its V-Go Wearable Insulin Delivery device , could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's ...

  • ACCESSWIRE3 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • ACCESSWIRE3 months ago

    Valeritas Holdings, New Study Results Pump Up V-Go Insulin Delivery Device

    NEW YORK, NY / ACCESSWIRE / June 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (VLRX) is a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. The company shares jumped this week after the company advised positive results from its ENABLE study, showing that patients who switched from insulin pens and syringes to the company's wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose. The VLRX primary target market consists of the approximately 5.6 million patients with type 2 diabetes who currently take injectable insulin, of which up to 4.5 million may not be achieving their target blood glucose goal.

  • GlobeNewswire3 months ago

    Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes

    Three poster presentations at the American Diabetes Association Meeting in Orlando, Florida, reported that patients who switched from insulin pens and syringes to V-Go significantly improved blood glucose while lowering insulin dose.

  • ACCESSWIRE4 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Valeritas and Three Other Medical Supplies Stocks

    Stock Research Monitor: ILMN, NXTM, and SIEN LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of VLRX earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Valeritas Holdings Inc Earnings Call

  • ACCESSWIRE4 months ago

    Free Post Earnings Research Report: Integra’s Quarterly Sales Surged 38%; Adjusted EPS Soared 49%

    LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free earnings report on Integra LifeSciences Holdings Corp. (NASDAQ: IART) ("Integra"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IART. The Company reported its first quarter fiscal 2018 operating and financial results on April 25, 2018. Additionally, the Company raised its revenue and earnings guidance for FY18.